Adaptilens announced a $1.6 million seed funding led by Pillar VC with additional participation from Accanto Partners. The company is developing an intraocular lens with the aim of allowing patients to live their lives free of glasses and contact lenses.

Adaptilens' flexible intraocular lens mimics the natural human lens, giving patients clear near, intermediate, and distance vision, by allowing the eye's ciliary muscles to change the implanted lens' shape, so that the eye can focus at a range of distances naturally.